1325P Long-term Survival and Health-Related Quality of Life in Patients Treated with Nivolumab for Advanced Non-Small Cell Lung Cancer: A Wide Prospective French Real-World Study (EVIDENS)

EVIDENS is a prospective, observational and multicenter study of NSCLC patients treated with nivolumab after prior chemotherapy. Prior report showed consistent outcomes as compared with randomized clinical trials1. We report here long-term overall survival (OS) and health-related quality of life (HRQoL). OS and progression-free survival were estimated using the Kaplan-Meier method with their 95% confidence intervals (CIs) and longitudinal HRQoL was assessed using EQ-5D-3L questionnaire and its associated Visual Analogic Scale (VAS; range: 0 to 100). Among the 1421 enrolled patients with advanced NSCLC, the 24- and 36-month OS rates were 29.4 % (95% CI: 26.9; 32.0) and 18.5% (95% CI: 15.6-21.6), respectively. With a minimum follow-up of 29 months, 13.1 % (95% CI: 11.3; 15.1) and 7.6 % (95% CI: 5.6; 9.9) of patients were progression-free survivors. At 24 months, the EQ-5D-3L and VAS were completed by 111 and 109 patients, respectively. The proportion of patients reporting no statistically change or improvement from baseline in the five dimensions of EQ-5D-3L was: self-care: 84.1%/4.7%; mobility: 72.0%/16.5%; anxiety-depression: 70.1%/15.9%; usual activities: 66.4%/14.0%; pain: 64.5%/19.6%. Mean VAS score at baseline was 71.7 [68.2; 75.2] and 74.5 [71.1; 77.8] at 24 months corresponding to a non-significant mean improvement from baseline of +2.76 [95%CI: -0.71; +6.23]. This analysis of advanced NSCLC patients treated in real-life with nivolumab showed a-long-term survival benefit consistent with the estimates from _randomized clinical trials2. Furthermore, HRQoL of patients was stable at 24 months. References 1Barlesi F et al. OncoImmunology:1,1744898,doi:10.1080/2162402X.2020.1744898 2Vokes EE et al. Ann Oncol 2018; 29: 959–65.